The company receives Health Canada approval for VYZULTA® (latanoprostene bunod ophthalmicsolution) 0.024% and Bepreve® (bepotastine besilate ophthalmic solution) 1.5%
Bausch + Lomb expands its Vision Care portfolio with the addition of Bausch + Lomb ULTRA® forAstigmatism contact lenses and Biotrue®ONEday for Astigmatism contact lenses
Bausch + Lomb introduces its next-generation phacoemulsification system, the Stellaris Elite®vision enhancement system, which offers cataract and retina capabilities in a single platform
FineVision® MICRO Trifocal IOL is approved, the first trifocal to be approved by Health Canada
Bausch + Lomb launches the latest evolution in excimer laser technology, the Technolas® Teneo™ 317 Model 2
In 2019, Bausch + Lomb launches the preservative-free dry eye relief lubricant; Biotrue® Eye Drops.